Moreover, in 2018, based on the results of the KEYNOTE-189 study, the combination of pembrolizumab, pemetrexed, and platinum was approved as the first-line treatment for the patients with metastatic non-squamous non-small-cell lung cancer (NSqNSCLC) and the patients lack EGFR or ALK genomic tumor aberrations (57). This evidence concerns the gene ALK and neoplasm.